Patent application number | Description | Published |
20080207715 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 08-28-2008 |
20080214620 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 09-04-2008 |
20080221086 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 09-11-2008 |
20080234313 | NOVEL INHIBITORS - Compounds of formula (I), combinations and uses thereof for disease therapy, | 09-25-2008 |
20080260688 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-23-2008 |
20080262063 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-23-2008 |
20080262065 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-23-2008 |
20080267911 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-30-2008 |
20080267912 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-30-2008 |
20080286231 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 11-20-2008 |
20080286810 | Use of Inhibtors of Glutaminyl Cyclases for Treatment and Prevention of Disease - Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity. | 11-20-2008 |
20080292582 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 11-27-2008 |
20080293618 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS - The present invention relates to DP IV-inhibitors of formula (1) | 11-27-2008 |
20090018087 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia. | 01-15-2009 |
20090149394 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES - The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o | 06-11-2009 |
20090269301 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 10-29-2009 |
20100040575 | USE OF INHIBITORS OF GLUTAMINYL CYCLASE AND GLUTAMATE CYCLASE FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES - Physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity. | 02-18-2010 |
20100099721 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Inhibitors of prolyl endopeptidase of formula 1 | 04-22-2010 |
20100119475 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of general formula (I): | 05-13-2010 |
20100125086 | USE OF ISOQC INHIBITORS - The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinising polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation. | 05-20-2010 |
20100159032 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS - The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof. | 06-24-2010 |
20100249149 | Inhibitors of Protein Kinases - are useful as inhibitors of cyclin dependent kinases such as CDK9. | 09-30-2010 |
20100273835 | NOVEL COMPOUNDS - The invention provides compounds of general formula (I) | 10-28-2010 |
20110092501 | NOVEL INHIBITORS - The invention relates to novel pyrrolidine derivatives of formula (I): | 04-21-2011 |
20110224225 | Inhibitors of protein kinases - Compounds of general Formula (I): | 09-15-2011 |
20110224254 | NOVEL INHIBITORS - Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 09-15-2011 |
20110224259 | NOVEL INHIBITORS - The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 09-15-2011 |
20110262388 | NOVEL INHIBITORS - Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 10-27-2011 |
20120237475 | Novel Inhibitors - Novel heterocyclic derivatives of formula (I): | 09-20-2012 |
20120283259 | NOVEL INHIBITORS - Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 11-08-2012 |
20120301398 | RADIOLABELLED GLUTAMINYL CYCLASE (QC) INHIBITORS AND USES OF SAME - Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors. | 11-29-2012 |
20130345233 | INHIBITORS OF PROTEIN KINASES - Compounds of general Formula (I): | 12-26-2013 |
20140065095 | NOVEL INHIBITORS - The invention relates to novel pyrrolidine derivatives of formula (I): | 03-06-2014 |
20150038516 | Inhibitors of Protein Kinases - Compounds of general Formula I: | 02-05-2015 |